CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
dexlansoprazole +1 moredrug
Likely dose
dexlansoprazole 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01093755
NCT01093755Phase 4Completed
CompareCT.gov

Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?: A Randomized Controlled Trial

Mayo Clinic·interventional·Posted Mar 26, 2010·Updated Mar 17, 2016

In Brief

A Phase 4 clinical trial evaluating dexlansoprazole and Omeprazole for Inflammation and Barrett's Esophagus. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The investigators hypothesize that intensive acid suppression with a long acting high potency proton pump inhibitor (PPI) drug dexlansoprazole will lead to a greater decrease in levels of inflammatory mediators (compared to conventional PPIs) in the esophagus, which could potentially lead to decreased recurrence of intestinal metaplasia following endoscopic ablation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation, Barrett's Esophagus
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 26, 2010
Enrollment StartMar 1, 2010
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 16.3 years ago

Interventions

dexlansoprazoledrug

Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months

Omeprazoledrug

Escalating doses of omeprazole (20-60 mg/day) for 6 months